Harika Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.49 Cr
as on 16-11-2024
- Company Age 35 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 12.00 Cr
as on 16-11-2024
- Satisfied Charges ₹ 9.70 Cr
as on 16-11-2024
- Revenue 4.46%
(FY 2023)
- Profit -17.20%
(FY 2023)
- Ebitda -11.99%
(FY 2023)
- Net Worth 15.17%
(FY 2023)
- Total Assets 24.01%
(FY 2023)
About Harika Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.49 Cr.
The company currently has active open charges totaling ₹12.00 Cr. The company has closed loans amounting to ₹9.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkata Adusumilli, Vijaya Uppalapati, and Amarnath Uppalapati serve as directors at the Company.
- CIN/LLPIN
U24230TG1989PTC010584
- Company No.
010584
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 1989
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Harika Drugs Private Limited offer?
Harika Drugs Private Limited offers a wide range of products and services, including Water Treatment & Purification Plant, Water Purification Plants.
Who are the key members and board of directors at Harika Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amarnath Uppalapati  | Managing Director | 24-Dec-1992 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Adusumilli | Director | 28-Aug-1995 | Current |
| Vijaya Uppalapati | Director | 07-Jan-2013 | Current |
Financial Performance of Harika Drugs.
Harika Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.46% increase. The company also saw a substantial fall in profitability, with a 17.2% decrease in profit. The company's net worth Soared by an impressive increase of 15.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harika Drugs?
In 2023, Harika Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Harika Labs Private LimitedActive 14 years 8 months
Vijaya Uppalapati and Amarnath Uppalapati are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Jan 2015 | ₹12.00 Cr | Open |
State Bank Of India Creation Date: 13 Feb 2006 | ₹9.70 Cr | Satisfied |
How Many Employees Work at Harika Drugs?
Harika Drugs has a workforce of 62 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harika Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harika Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
